Medical factors influencing decision making regarding radiation therapy for breast cancer

Christina A Dilaveri, Nicole P Sandhu, Lonzetta Neal, Michelle A Neben-Wittich, Tina J Hieken, Maire Brid Mac Bride, Dietlind L Wahner-Roedler, Karthik Ghosh, Christina A Dilaveri, Nicole P Sandhu, Lonzetta Neal, Michelle A Neben-Wittich, Tina J Hieken, Maire Brid Mac Bride, Dietlind L Wahner-Roedler, Karthik Ghosh

Abstract

Radiation therapy is an important and effective adjuvant therapy for breast cancer. Numerous health conditions may affect medical decisions regarding tolerance of breast radiation therapy. These factors must be considered during the decision-making process after breast-conserving surgery or mastectomy for breast cancer. Here, we review currently available evidence focusing on medical conditions that may affect the patient-provider decision-making process regarding the use of radiation therapy.

Keywords: cardiac devices; connective tissue disease; prior radiation.

References

    1. Darby S, McGale P, Correa C, et al. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–1716.
    1. Yadav BS, Sharma SC, Singh R, Singh G, Kumar V. Postmastectomy radiation and survival in patients with breast cancer. J Cancer Res Ther. 2007;3(4):218–224.
    1. Recht A, Edge SB. Evidence-based indications for postmastectomy irradiation. Surg Clin North Am. 2003;83(4):995–1013.
    1. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
    1. Carver JR, Shapiro CL, Ng A, et al. ASCO Cancer Survivorship Expert Panel American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25(25):3991–4008.
    1. Giordano SH, Kuo YF, Freeman JL, Buchholz TA, Hortobagyi GN, Goodwin JS. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst. 2005;97(6):419–424.
    1. Darby SC, Ewertz M, Hall P. Ischemic heart disease after breast cancer radiotherapy. N Engl J Med. 2013;368(26):2527.
    1. Cuzick J, Stewart H, Rutqvist L, et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol. 1994;12(3):447–453.
    1. Correa CR, Litt HI, Hwang WT, Ferrari VA, Solin LJ, Harris EE. Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J Clin Oncol. 2007;25(21):3031–3037.
    1. Hooning MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007;99(5):365–375.
    1. Wang W, Wainstein R, Freixa X, Dzavik V, Fyles A. Quantitative coronary angiography findings of patients who received previous breast radiotherapy. Radiother Oncol. 2011;100(2):184–188.
    1. Park CK, Li X, Starr J, Harris EE. Cardiac morbidity and mortality in women with ductal carcinoma in situ of the breast treated with breast conservation therapy. Breast J. 2011;17(5):470–476.
    1. Nilsson G, Holmberg L, Garmo H, et al. Distribution of coronary artery stenosis after radiation for breast cancer. J Clin Oncol. 2012;30(4):380–386.
    1. Marbach JR, Sontag MR, Van Dyk J, Wolbarst AB. Management of radiation oncology patients with implanted cardiac pacemakers: report of AAPM Task Group No 34. American Association of Physicists in Medicine. Med Phys. 1994;21(1):85–90.
    1. Gelblum DY, Amols H. Implanted cardiac defibrillator care in radiation oncology patient population. Int J Radiat Oncol Biol Phys. 2009;73(5):1525–1531.
    1. Soejima T, Yoden E, NIshimura Y, et al. Radiation therapy in patients with implanted cardiac pacemakers and implantable cardioverter defibrillators: a prospective survey in Japan. J Radiat Res. 2011;52(4):516–521.
    1. Munshi A, Wadasadawala T, Sharma PK, et al. Radiation therapy planning of a breast cancer patient with in situ pacemaker – challenges and lessons. Acta Oncol. 2008;47(2):255–260.
    1. Wadasadawala T, Pandey A, Agarwal JP, et al. Radiation therapy with implanted cardiac pacemaker devices: a clinical and dosimetric analysis of patients and proposed precautions. Clin Oncol (R Coll Radiol) 2011;23(2):79–85.
    1. Kapa S, Fong L, Blackwell CR, Herman MG, Schomberg PJ, Hayes DL. Effects of scatter radiation on ICD and CRT function. Pacing Clin Electrophysiol. 2008;31(6):727–732.
    1. Nibhanupudy JR, de Jesus MA, Fujita M, Goldson AL. Radiation dose monitoring in a breast cancer patient with a pacemaker: a case report. J Natl Med Assoc. 2001;93(7–8):278–281.
    1. Minor GI, Yashar CM, Spanos WJ, Jr, et al. The relationship of radiation pneumonitis to treated lung volume in breast conservation therapy. Breast J. 2006;12(1):48–52.
    1. Lingos TI, Recht A, Vicini F, Abner A, Silver B, Harris JR. Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 1991;21(2):355–360.
    1. Jung JI, Kim HH, Park SH, et al. Thoracic manifestations of breast cancer and its therapy. Radiographics. 2004;24(5):1269–1285.
    1. Stone DJ, Schwartz MJ, Green RA. Fatal pulmonary insufficiency due to radiation effect upon the lung. Am J Med. 1956;21(2):211–226.
    1. Bennett DE, Million RR, Ackerman LV. Bilateral radiation pneumonitis, a complication of the radiotherapy of bronchogenic carcinoma. (Report and analysis of seven cases with autopsy) Cancer. 1969;23(5):1001–1018.
    1. Whelan TJ, Olivotto I, Ackerman I, et al. NCIC-CTG MA.20: an intergroup trial of regional nodal irradiation in early breast cancer [abstract] J Clin Oncol. 2011;29(Suppl 15):LBA1003.
    1. Morris MM, Powell SN. Irradiation in the setting of collagen vascular disease: acute and late complications. J Clin Oncol. 1997;15(7):2728–2735.
    1. Ross JG, Hussey DH, Mayr NA, Davis CS. Acute and late reactions to radiation therapy in patients with collagen vascular diseases. Cancer. 1993;71(11):3744–3752.
    1. Mayr NA, Riggs CE, Saag KG, Wen BC, Pennington EC, Hussey DH. Mixed connective tissue disease and radiation toxicity. A case report. Cancer. 1997;79(3):612–618.
    1. Pinn ME, Gold DG, Petersen IA, Osborn TG, Brown PD, Miller RC. Systemic lupus erythematosus, radiotherapy, and the risk of acute and chronic toxicity: the Mayo Clinic Experience. Int J Radiat Oncol Biol Phys. 2008;71(2):498–506.
    1. Gold DG, Miller RC, Petersen IA, Osborn TG. Radiotherapy for malignancy in patients with scleroderma: The Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 2007;67(2):559–567.
    1. Chen AM, Obedian E, Haffty BG. Breast-conserving therapy in the setting of collagen vascular disease. Cancer J. 2001;7(6):480–491.
    1. Charalambous H, Bloomfield D. Psoriasis and radiotherapy: exacerbation of psoriasis following radiotherapy for carcinoma of the breast (the Koebner phenomenon) Clin Oncol (R Coll Radiol) 2000;12(3):192–193.
    1. Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica. 1974;148(1):1–18.
    1. Munshi A, Jain S, Budrukkar A, Jalali R, Sarin R. Radiotherapy-induced depigmentation in a patient with breast cancer. Indian J Cancer. 2007;44(4):157–158.
    1. Chadha M, Trombetta M, Boolbol S, Osborne MP. Managing a small recurrence in the previously irradiated breast. Is there a second chance for breast conservation? Oncology (Williston Park) 2009;23(11):933–940.
    1. Solin LJ, Gray R, Goldstein LJ, et al. Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. Breast Cancer Res Treat. 2012;134(2):683–692.
    1. Chadha M, Feldman S, Boolbol S, Wang L, Harrison LB. The feasibility of a second lumpectomy and breast brachytherapy for localized cancer in a breast previously treated with lumpectomy and radiation therapy for breast cancer. Brachytherapy. 2008;7(1):22–28.
    1. Trombetta M, Julian T, Miften M, McWilliams W, Kim Y, Parda D. The use of the MammoSite balloon applicator in re-irradiation of the breast. Brachytherapy. 2008;7(4):316–319.
    1. Guix B, Lejárcegui JA, Tello JI, et al. Exeresis and brachytherapy as salvage treatment for local recurrence after conservative treatment for breast cancer: results of a ten-year pilot study. Int J Radiat Oncol Biol Phys. 2010;78(3):804–810.
    1. Deutsch M. Repeat high-dose external beam irradiation for in-breast tumor recurrence after previous lumpectomy and whole breast irradiation. Int J Radiat Oncol Biol Phys. 2002;53(3):687–691.
    1. Hannoun-Levi JM, Houvenaeghel G, Ellis S, et al. Partial breast irradiation as second conservative treatment for local breast cancer recurrence. Int J Radiat Oncol Biol Phys. 2004;60(5):1385–1392.
    1. Baglan KL, Sharpe MB, Jaffray D, et al. Accelerated partial breast irradiation using 3D conformal radiation therapy (3D-CRT) Int J Radiat Oncol Biol Phys. 2003;55(2):302–311.
    1. Formenti SC, Truong MT, Goldberg JD, et al. Prone accelerated partial breast irradiation after breast-conserving surgery: preliminary clinical results and dose-volume histogram analysis. Int J Radiat Oncol Biol Phys. 2004;60(2):493–504.
    1. Kozak KR, Katz A, Adams J, et al. Dosimetric comparison of proton and photon three-dimensional, conformal, external beam accelerated partial breast irradiation techniques. Int J Radiat Oncol Biol Phys. 2006;65(5):1572–1578.
    1. Chadha M, Yoon H, Feldman S, Shah N, Moore E, Harrison LB. Partial breast brachytherapy as the primary treatment for breast cancer diagnosed after mantle radiation therapy for Hodgkin’s disease. Am J Clin Oncol. 2009;32(2):132–136.
    1. Intra M, Gentilini O, Veronesi P, et al. A new option for early breast cancer patients previously irradiated for Hodgkin’s disease: intraoperative radiotherapy with electrons (ELIOT) Breast Cancer Res. 2005;7(5):R828–R832.
    1. Deutsch M, Gerszten K, Bloomer WD, Avisar E. Lumpectomy and breast irradiation for breast cancer arising after previous radiotherapy for Hodgkin’s disease or lymphoma. Am J Clin Oncol. 2001;24(1):33–34.
    1. Aref I, Cross P. Conservative surgery and radiation therapy for early stage breast cancer after previous mantle radiation for Hodgkin’s disease. Br J Radiol. 2000;73(872):905–906.
    1. National Toxicology Program . Report on Carcinogens 12th ed. 2011. Washington, DC: US Department of Health and Human Services; 2011. [Accessed September 28, 2014]. Available from: .
    1. Scully R, Livingston DM. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature. 2000;408(6811):429–432.
    1. Goss PE, Sierra S. Current perspectives on radiation-induced breast cancer. J Clin Oncol. 1998;16(1):338–347.
    1. Pierce LJ, Strawderman M, Narod SA, et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol. 2000;18(19):3360–3369.
    1. Kirova YM, Savignoni A, Sigal-Zafrani B, et al. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature. Breast Cancer Res Treat. 2010;120(1):119–126.
    1. Metcalfe K, Lubinski J, Lynch HT, et al. Hereditary Breast Cancer Clinical Study Group Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. J Natl Cancer Inst. 2010;102(24):1874–1878.
    1. Haffty BG, Harrold E, Khan AJ, et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet. 2002;359(9316):1471–1477.
    1. Garcia-Etienne CA, Barile M, Gentilini OD, et al. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer? Ann Surg Oncol. 2009;16(12):3380–3387.
    1. Kast K, Krause M, Schuler M, et al. Late onset Li-Fraumeni Syndrome with bilateral breast cancer and other malignancies: case report and review of the literature. BMC Cancer. 2012;12:217.
    1. Goi K, Takagi M, Iwata S, et al. DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation. Cancer Res. 1997;57(10):1895–1902.
    1. Delia D, Goi K, Mizutani S, et al. Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations. Oncogene. 1997;14(18):2137–2147.
    1. Limacher JM, Frebourg T, Natarajan-Ame S, Bergerat JP. Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer. 2001;96(4):238–242.
    1. Salmon A, Amikam D, Sodha N, et al. Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline ‘de-novo’ TP53 mutation. Clin Oncol (R Coll Radiol) 2007;19(7):490–493.
    1. Heymann S, Delaloge S, Rahal A, et al. Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol. 2010;5:104.
    1. Bennett KL, Mester J, Eng C. Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome. JAMA. 2010;304(24):2724–2731.
    1. Iannuzzi CM, Atencio DP, Green S, Stock RG, Rosenstein BS. ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int J Radiat Oncol Biol Phys. 2002;52(3):606–613.
    1. Bernstein JL, Haile RW, Stovall M, et al. WECARE Study Collaborative Group Radiation exposure, the ATM Gene, and contralateral breast cancer in the women’s environmental cancer and radiation epidemiology study. J Natl Cancer Inst. 2010;102(7):475–483.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner